An Operational Guide for GLP-1 Prescribing Under the 2026 Medicare Bridge Program

Editor’s Note: The Medicare GLP-1 Bridge Program and the subsequent BALANCE Model are evolving federal initiatives. This information is subject to change based on upcoming CMS guidance and federal rulemaking.

Key Takeaways:

• The Medicare Bridge Program formally treats obesity as a chronic disease rather than a "lifestyle" condition in the Medicare population.
• It opens treatment to anyone with a BMI of 35 (or 27 with specific comorbidities) under federal guidelines.
• The Bridge Program serves as the high-stakes test run for the permanent, mandatory BALANCE Model.

As of 2026, the obesity management landscape has undergone a seismic shift with the launch of the Medicare GLP-1 Bridge Program. For years, clinicians have navigated the "weight loss exclusion" of the Social Security Act, often leaving older patients with obesity without affordable access to life-changing incretin therapies.^1,2

The Bridge Program – running from July 1 to December 31, 2027 – serves as a critical transition toward the upcoming BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model. For the first time, Medicare Part D beneficiaries can access GLP-1 receptor agonists (GLP-1s) specifically for chronic weight management with a standardized, predictable cost structure.^1,2

Patient eligibility and clinical criteria

The Bridge Program does not grant universal coverage for all patients with an elevated BMI. To qualify, clinicians must attest that the patient meets specific thresholds during the Prior Authorization (PA) process.^1-3

Primary eligibility categories

A patient qualifies if they have any of the following:^1-3

• Class 2/3 Obesity – BMI ≥ 35 with no required comorbidities
• Overweight with comorbidities – BMI ≥ 27 plus at least one of: pre-diabetes, hypertension, CKD (Stage 3a+), or heart failure
• Established cardiovascular disease – Any BMI ≥ 27 with a history of myocardial infarction, stroke, or peripheral arterial disease

The prescribing workflow: Centralized processing

The most significant operational change in 2026 is that Bridge Program prescriptions do not go through the patient’s Part D plan. Instead, CMS has established a central processor to manage claims and PAs.^1-3

Operational steps for the clinic:^1-3

• Verification – Confirm the patient is enrolled in a standalone Prescription Drug Plan (PDP) or Medicare Advantage (MA-PD).
• Submission – Send the e-prescription and PA request to the central processor (details to be made available via CMS provider portal).
• Pharmacy coordination – Ensure the patient uses a participating pharmacy. The pharmacy must use a specific BIN/PCN (Banking Identification Number/Processor Control Number) provided by CMS to bypass the standard Part D ledger (AMCP, 2026).
• Cost to patient – Eligible patients pay a fixed monthly fee. Importantly, these payments do not contribute to the annual out-of-pocket maximum, as the program operates independently of the standard benefit structure.

Coding and documentation essentials

While the medication is processed centrally, your clinical encounter must still be coded accurately for reimbursement and to support the medical necessity of the GLP-1 therapy.^1,4

ICD-10-CM coding

Specificity is paramount for Bridge Program audits. Always include:⁴

• E66.01 – Morbid (severe) obesity due to excess calories
• E66.3 – Overweight (for those in the BMI 27 to 29.9 range)
• Z68.XX – BMI status codes (e.g., Z68.35 for BMI 35.0 to 35.9).

CPT and HCPCS coding

For the clinical visit and ongoing obesity counseling, utilize:⁴

• G0447 – Face-to-face behavioral counseling for obesity, 15 minutes. Medicare covers this for patients with a BMI ≥ 30.
• 99213–99215 – Established patient E/M visits. Ensure documentation reflects the complexity of managing multi-system metabolic health and potential GLP-1 side effects.

Medication selection in 2026

Under the Bridge Program, coverage is limited to specific FDA-approved formulations for weight loss. As of April 2026, the following are included:^1-3

• Foundayo® (orforglipron) – Oral tablet formulation
• Wegovy® (semaglutide) – Both injectable and the newly released tablet formulations
• Zepbound® (tirzepatide) – Specifically, the KwikPen® formulation

Clinical management in older patients

Prescribing for the 65+ demographic requires a "start low, go slow" approach. Clinical data suggest that while GLP-1s are highly effective, older adults are at a higher risk for sarcopenia.⁵

When prescribing GLP-1s to older patients, clinicians should emphasize a protein-forward diet and resistance training to preserve lean body mass. Regular monitoring of renal function is also advised, especially in patients with pre-existing chronic kidney disease.⁵

Promise in treating seniors with obesity

The 2026 Medicare GLP-1 Bridge Program represents a historic opportunity to treat obesity as the chronic disease it is. By mastering the centralized PA process, utilizing specific ICD-10 coding, and focusing on the unique physiological needs of older adults, clinicians can ensure their patients successfully transition to the permanent BALANCE model in 2027.^1-3